Compass Therapeutics, Inc.

CMPXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1738021

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$42.3M	$38.1M	—	—	—
Operating Expenses	$57.5M	$50.4M	$41.7M	$81.9M	$27.8M
Operating Income (Loss)	-$56.6M	-$50.4M	-$41.7M	-$81.9M	-$27.8M
Interest Expense	—	—	—	$370.0K	$908.0K
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$39.2M	-$82.2M	-$29.5M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$32.0K
Net Income (Loss) Attributable to Parent	-$49.4M	-$42.5M	-$39.2M	-$82.2M	-$29.5M
Earnings Per Share, Basic	-$0.36	-$0.33	-$0.37	-$1.31	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$140.4M	$156.9M	$199.6M	$153.8M	$51.9M
Assets, Current	$132.8M	$153.9M	$194.8M	$147.1M	$50.2M
Cash and Cash Equivalents, at Carrying Value	$43.5M	$24.2M	$34.9M	$144.5M	$47.1M
Liabilities	$15.2M	$8.3M	$18.0M	$13.7M	$12.0M
Liabilities, Current	$8.9M	$7.8M	$16.2M	$10.6M	$10.1M
Long-term Debt, Excluding Current Maturities	—	—	—	—	$1.9M
Accounts Payable, Current	$2.2M	$4.1M	$3.4M	$867.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$44.9M	-$40.6M	-$34.1M	-$19.7M	-$26.8M
Net Cash Provided by (Used in) Investing Activities	$46.8M	$27.0M	-$151.2M	-$1.8M	$38.0K
Net Cash Provided by (Used in) Financing Activities	$17.3M	$2.9M	$75.8M	$118.6M	$48.5M
Payments to Acquire Property, Plant, and Equipment	$44.0K	$30.0K	$212.0K	$1.6M	$106.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)